HUTCHMED H1 Earnings Call Highlights
Yahoo Finance · Jul 30, 2026 · HCM (HCM)
HUTCHMED (NASDAQ:HCM) reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported results. The company maintained its full-year oncology revenue guidance of $330 million to $415 milli
Not investment advice. Cached headline, not a full reprint.